Search results
Showing 3101 to 3150 of 3765 results for treatment
Discontinued Reference number: GID-TA11655
NaviCam for diagnosing gastrointestinal tract conditions (MIB104)
NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Preparing for the next breakthroughs in liver disease treatments With no licensed treatments for MASH, a serious liver...
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
View recommendations for IPG808Show all sections
this applies to you, because it may not be safe for you to reduce or stop treatment. Street benzos Street benzos are street drugs which...
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...
In development Reference number: GID-TA11406 Expected publication date: TBC
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Violent and aggressive behaviours in people with mental health problems (QS154)
This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.
View quality statements for QS154Show all sections
Sections for QS154
- Quality statements
- Quality statement 1: Identifying triggers and warning signs
- Quality statement 2: Preventing and managing violent or aggressive behaviour
- Quality statement 3: Physical health during and after manual restraint
- Quality statement 4: Physical health after rapid tranquillisation
- Quality statement 5: Immediate post-incident debrief
- About this quality standard
Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.
This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).
Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board
In development Reference number: GID-TA11301 Expected publication date: TBC
Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details
Outside interests of the NICE board
describe details of patient selection, particularly in relation to previous treatments. They should also describe clinical outcomes...
SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)
NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .
Curos for preventing infections when using needleless connectors (HTG510)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?
are at high risk of infection, or who would find it difficult to access treatment at a later date if they screened positive for a...
sepsis, but they agreed that if concerns are enough to warrant antibiotic treatment, more frequent observations are needed because of...
NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .
The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)
NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias
Older people with social care needs and multiple long-term conditions (NG22)
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.
Discontinued Reference number: GID-TAG360
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.
Thopaz+ portable digital system for managing chest drains (HTG465)
Evidence-based recommendations on Thopaz+ for managing chest drains.
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued Reference number: GID-TAG321
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
hypertension. Details of patient selection, all complications, and subsequent treatments and interventions for pulmonary hypertension...
This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04
In development Reference number: GID-TA11771 Expected publication date: TBC
Discontinued Reference number: GID-TAG422